Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis

Objective Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a diseas...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 68; no. 2; pp. 494 - 504
Main Authors Mavropoulos, Athanasios, Simopoulou, Theodora, Varna, Areti, Liaskos, Christos, Katsiari, Christina G., Bogdanos, Dimitrios P., Sakkas, Lazaros I.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.02.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objective Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Methods Forty‐five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc‐associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)–associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24highCD38high) and memory Breg cells (CD19+CD27+CD24high) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL‐10 after B cell activation. In addition, activation of p38 MAPK and STAT‐3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll‐like receptor 9 (TLR‐9). Results Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc‐associated PF (1.52 ± 0.17%), and those with RA‐associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL‐10 by Breg cells after stimulation with TLR‐9 was impaired in patients with SSc, particularly those with SSc‐associated PF. Activation of STAT‐3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR‐9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc‐associated PF. Conclusion This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT‐3 activation upon stimulation with BCR and TLR‐9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.
AbstractList Objective Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Methods Forty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24highCD38high) and memory Breg cells (CD19+CD27+CD24high) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9). Results Percentages of memory Breg cells were decreased in patients with early SSc (mean±SEM 1.85± 0.38%), those with established SSc (1.6±0.88%), those with SSc-associated PF (1.52±0.17%), and those with RA-associated PF (1.58±0.26%), compared to healthy controls (6.3±0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF. Conclusion This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.
Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Forty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24(high) CD38(high) ) and memory Breg cells (CD19+CD27+CD24(high) ) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9). Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc-associated PF (1.52 ± 0.17%), and those with RA-associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF. This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.
Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies.OBJECTIVEBreg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies.Forty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24(high) CD38(high) ) and memory Breg cells (CD19+CD27+CD24(high) ) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9).METHODSForty-five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc-associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)-associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24(high) CD38(high) ) and memory Breg cells (CD19+CD27+CD24(high) ) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL-10 after B cell activation. In addition, activation of p38 MAPK and STAT-3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll-like receptor 9 (TLR-9).Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc-associated PF (1.52 ± 0.17%), and those with RA-associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF.RESULTSPercentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc-associated PF (1.52 ± 0.17%), and those with RA-associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL-10 by Breg cells after stimulation with TLR-9 was impaired in patients with SSc, particularly those with SSc-associated PF. Activation of STAT-3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR-9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc-associated PF.This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.CONCLUSIONThis is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT-3 activation upon stimulation with BCR and TLR-9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.
Objective Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing autoimmunity. This study was undertaken to examine the number and function of Breg cells in patients with systemic sclerosis (SSc), a disease with many autoantibodies. Methods Forty‐five patients with SSc (12 with early SSc, 33 with established disease including 16 with SSc‐associated pulmonary fibrosis [PF]), 12 healthy control subjects, and 10 patients with rheumatoid arthritis (RA)–associated PF were studied. The phenotypes of immature/transitional Breg cells (CD19+CD24highCD38high) and memory Breg cells (CD19+CD27+CD24high) were evaluated by flow cytometry. The function of Breg cells was assessed by measuring the production of IL‐10 after B cell activation. In addition, activation of p38 MAPK and STAT‐3 was measured following stimulation of the cells with B cell receptor (BCR) and Toll‐like receptor 9 (TLR‐9). Results Percentages of memory Breg cells were decreased in patients with early SSc (mean ± SEM 1.85 ± 0.38%), those with established SSc (1.6 ± 0.88%), those with SSc‐associated PF (1.52 ± 0.17%), and those with RA‐associated PF (1.58 ± 0.26%), compared to healthy controls (6.3 ± 0.49%; each P < 0.001). Percentages of transitional Breg cells were also decreased. Expression of IL‐10 by Breg cells after stimulation with TLR‐9 was impaired in patients with SSc, particularly those with SSc‐associated PF. Activation of STAT‐3 and p38 MAPK was impaired in naive and memory B cells from patients with SSc after stimulation with BCR and TLR‐9. Expression of the stimulatory CD19 receptor was increased in B cells and also increased, to a lesser extent, in Breg cells from patients with SSc compared to healthy controls. Percentages of memory B cells were decreased in patients with SSc, particularly in those with SSc‐associated PF. Conclusion This is the first study to demonstrate that Breg cells are phenotypically and functionally impaired in patients with SSc. Furthermore, in SSc, B cells exhibit impaired p38 MAPK and STAT‐3 activation upon stimulation with BCR and TLR‐9. The findings of decreased numbers of Breg cells along with increased expression of CD19 support the idea of B cell autoaggression acting as an immunopathogenic mediator in SSc.
Author Simopoulou, Theodora
Mavropoulos, Athanasios
Varna, Areti
Liaskos, Christos
Bogdanos, Dimitrios P.
Sakkas, Lazaros I.
Katsiari, Christina G.
Author_xml – sequence: 1
  givenname: Athanasios
  surname: Mavropoulos
  fullname: Mavropoulos, Athanasios
  organization: University of Thessaly
– sequence: 2
  givenname: Theodora
  surname: Simopoulou
  fullname: Simopoulou, Theodora
  organization: University of Thessaly
– sequence: 3
  givenname: Areti
  surname: Varna
  fullname: Varna, Areti
  organization: University of Thessaly
– sequence: 4
  givenname: Christos
  surname: Liaskos
  fullname: Liaskos, Christos
  organization: University of Thessaly
– sequence: 5
  givenname: Christina G.
  surname: Katsiari
  fullname: Katsiari, Christina G.
  organization: University of Thessaly
– sequence: 6
  givenname: Dimitrios P.
  surname: Bogdanos
  fullname: Bogdanos, Dimitrios P.
  organization: University of Thessaly
– sequence: 7
  givenname: Lazaros I.
  surname: Sakkas
  fullname: Sakkas, Lazaros I.
  organization: University of Thessaly
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26414243$$D View this record in MEDLINE/PubMed
BookMark eNp9kclKBDEQhoMo7gdfQAJe9DCavTvHcVxBVFzw2KTTNRrpZUzSyLy9GWfGg6B1qaLqq4K__i202nYtILRHyTElhJ0YH4-5FjxbQZuMMzWQjMjVZU013UC7IbyTFDojish1tMGUoIIJvonKUw-veAR1HfDQA77tG_DOmrqe4jOwHkyACpu2whd9a6Pr2u_RdTMxzqeJa_G9iQ7aGPCLi2_4cRoiNM7iR1uD74ILO2htbOoAu4u8jZ4vzp9GV4Obu8vr0fBmYLnk2UCY0lY51WBSqiRopfJc6DL1AcaqKg2RY8I15CaXTEpRZYJbppUtiaSq4tvocH534ruPHkIsGhdsUmZa6PpQ0EwRzQTJRUIPfqHvXe-TtBklteS5EiRR-wuqLxuoiol3jfHTYvm9BBzNAZuEBg_jH4SSYmZOkcwpvs1J7Mkv1rpoZg-N3rj6v41PV8P079PF8OFpvvEFCbqfJQ
CitedBy_id crossref_primary_10_3389_fimmu_2022_818814
crossref_primary_10_1097_MPH_0000000000002414
crossref_primary_10_1111_cei_13477
crossref_primary_10_1002_art_39820
crossref_primary_10_3389_fimmu_2018_02835
crossref_primary_10_1007_s12640_020_00234_9
crossref_primary_10_1016_j_jid_2021_05_038
crossref_primary_10_3389_fimmu_2021_739186
crossref_primary_10_1016_j_rcreu_2023_09_001
crossref_primary_10_1016_j_semarthrit_2016_10_003
crossref_primary_10_3389_fpubh_2020_00077
crossref_primary_10_1016_j_trsl_2019_02_010
crossref_primary_10_1136_rmdopen_2016_000384
crossref_primary_10_1016_j_autrev_2021_102755
crossref_primary_10_1136_ard_2021_221925
crossref_primary_10_1016_j_autrev_2017_10_015
crossref_primary_10_1016_j_semarthrit_2018_10_007
crossref_primary_10_1016_j_jaut_2020_102526
crossref_primary_10_1038_srep27479
crossref_primary_10_3389_fimmu_2022_1075813
crossref_primary_10_1080_10428194_2024_2434170
crossref_primary_10_1186_s13075_020_02153_8
crossref_primary_10_1016_j_clim_2017_04_013
crossref_primary_10_3389_fimmu_2017_00053
crossref_primary_10_3390_ijms23137080
crossref_primary_10_1016_j_rcreue_2019_03_004
crossref_primary_10_1016_j_clim_2017_04_010
crossref_primary_10_1007_s12026_020_09124_w
crossref_primary_10_1093_rheumatology_kez204
crossref_primary_10_1007_s00296_018_4076_3
crossref_primary_10_1016_j_jneuroim_2021_577520
crossref_primary_10_1002_pros_23391
crossref_primary_10_1172_JCI85113
crossref_primary_10_1007_s10067_021_05733_4
crossref_primary_10_1016_j_jaut_2024_103326
crossref_primary_10_1007_s10067_022_06137_8
crossref_primary_10_1111_cea_13439
crossref_primary_10_1007_s10067_017_3880_6
crossref_primary_10_3390_cells9010077
crossref_primary_10_1182_bloodadvances_2017011072
crossref_primary_10_1002_cia2_12059
crossref_primary_10_1007_s10620_018_4977_8
crossref_primary_10_1093_intimm_dxac048
crossref_primary_10_1093_rheumatology_keac406
crossref_primary_10_3389_fneur_2022_808322
crossref_primary_10_1097_BOR_0000000000000394
crossref_primary_10_3389_fimmu_2023_1125257
crossref_primary_10_3390_biomedicines10092150
crossref_primary_10_1186_s13075_016_1213_9
crossref_primary_10_1007_s00296_019_04261_4
crossref_primary_10_1007_s12026_017_8926_y
crossref_primary_10_1038_s41584_019_0184_z
crossref_primary_10_1007_s13317_018_0109_x
crossref_primary_10_1016_j_jim_2018_10_002
crossref_primary_10_3390_ph15080936
crossref_primary_10_1016_j_semcdb_2019_12_007
crossref_primary_10_1111_imr_12941
crossref_primary_10_1371_journal_pone_0180726
crossref_primary_10_1016_j_jds_2023_12_024
crossref_primary_10_1007_s10067_017_3553_5
crossref_primary_10_1080_14737159_2017_1356722
crossref_primary_10_1016_j_autrev_2025_103782
crossref_primary_10_1007_s00296_019_04357_x
crossref_primary_10_1016_j_clim_2024_110195
crossref_primary_10_1093_rheumatology_keab257
crossref_primary_10_3390_cells8121527
crossref_primary_10_3390_ijms232416154
crossref_primary_10_3390_jcm10020292
crossref_primary_10_3390_jcm8050625
crossref_primary_10_1007_s12016_021_08889_8
crossref_primary_10_1097_BOR_0000000000000898
crossref_primary_10_3389_fimmu_2022_933468
crossref_primary_10_1007_s10067_021_05665_z
crossref_primary_10_1016_j_revmed_2016_02_016
crossref_primary_10_3390_ijms20246152
crossref_primary_10_1016_j_imlet_2019_08_004
crossref_primary_10_1016_j_cellimm_2021_104412
crossref_primary_10_1016_j_rcreu_2019_03_002
crossref_primary_10_3389_fimmu_2018_01372
crossref_primary_10_1186_s13075_020_02226_8
crossref_primary_10_3390_ijms22062877
crossref_primary_10_3390_ph16081066
crossref_primary_10_1093_rheumatology_keac578
crossref_primary_10_1007_s10067_024_07086_0
crossref_primary_10_47360_1995_4484_2020_395_400
crossref_primary_10_3889_oamjms_2019_070
crossref_primary_10_1016_j_cca_2021_07_006
crossref_primary_10_1371_journal_pbio_3001513
crossref_primary_10_7717_peerj_8370
crossref_primary_10_1016_j_jaad_2021_10_066
crossref_primary_10_1016_j_clim_2019_07_012
crossref_primary_10_3389_fimmu_2024_1373464
crossref_primary_10_1016_j_imlet_2017_11_004
crossref_primary_10_1007_s12016_017_8608_5
crossref_primary_10_1007_s12016_016_8572_5
crossref_primary_10_1016_j_clindermatol_2024_12_007
crossref_primary_10_1097_MPH_0000000000002160
crossref_primary_10_1016_j_rcreue_2024_05_002
crossref_primary_10_3389_fimmu_2022_941011
crossref_primary_10_1080_07853890_2023_2208373
crossref_primary_10_1186_s12887_024_04622_4
crossref_primary_10_1093_stcltm_szad010
crossref_primary_10_1155_2018_8197937
crossref_primary_10_3389_fimmu_2019_02500
crossref_primary_10_3389_fimmu_2022_925741
crossref_primary_10_1080_16078454_2019_1622292
crossref_primary_10_1080_17843286_2017_1372244
crossref_primary_10_1186_s13075_019_1889_8
crossref_primary_10_3389_fimmu_2024_1326823
crossref_primary_10_1007_s10072_017_2932_7
crossref_primary_10_4049_jimmunol_1801211
Cites_doi 10.1016/j.cellimm.2012.01.007
10.4049/jimmunol.165.11.6635
10.4049/jimmunol.0900270
10.1172/JCI0215078
10.1111/j.1365-2249.2009.04059.x
10.1002/art.1780310302
10.1182/blood-2004-11-4284
10.1016/j.molimm.2014.05.018
10.1073/pnas.94.1.208
10.1002/art.1780230510
10.1182/blood-2010-07-294249
10.1186/ar4352
10.1093/rheumatology/keu149
10.2119/molmed.2011.00333
10.1172/JCI46274
10.1136/annrheumdis-2012-202986
10.1002/art.20274
10.1038/nm.3554
10.1084/jem.20111675
10.1002/art.20276
10.1038/ncprheum0346
10.1111/j.1600-065X.2008.00661.x
10.1007/978-1-4939-1161-5_4
10.1371/journal.pone.0049835
10.1182/blood-2004-07-2782
10.1002/art.23995
10.1016/j.autrev.2011.11.018
10.1038/ni833
10.1016/j.immuni.2008.03.017
10.1046/j.1523-1747.2003.12097.x
10.1016/j.jneuroim.2011.01.009
10.1182/blood-2012-11-465658
10.1093/rheumatology/kep093
10.1002/art.21646
10.1186/ar2965
10.1073/pnas.1635114100
10.3349/ymj.2011.52.5.851
10.1002/art.24249
10.1126/scitranslmed.3005407
10.1093/rheumatology/keu136
10.1016/j.jaci.2013.01.014
10.1056/NEJMoa052955
10.1186/ar3907
10.1016/j.immuni.2009.11.009
10.1182/blood-2014-04-571125
10.1016/j.clim.2007.11.013
10.1002/eji.201344341
10.4049/jimmunol.177.3.1581
10.1016/j.ajpath.2012.03.010
10.1084/jem.20021293
10.1038/nature11501
10.1016/j.clim.2008.09.009
ContentType Journal Article
Copyright 2016, American College of Rheumatology
2016, American College of Rheumatology.
Copyright_xml – notice: 2016, American College of Rheumatology
– notice: 2016, American College of Rheumatology.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
DOI 10.1002/art.39437
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Toxicology Abstracts
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2326-5205
EndPage 504
ExternalDocumentID 3932107211
26414243
10_1002_art_39437
ART39437
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: University of Thessaly, Greece
– fundername: Special Fund for Research Grants (ELKE)
GroupedDBID 0R~
1OC
24P
33P
3SF
4.4
52O
52U
52V
53G
5VS
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCUV
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
DCZOG
DIK
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
EX3
F00
FUBAC
G-S
G.N
GODZA
HGLYW
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
NF~
O66
O9-
OK1
OVD
P2W
PQQKQ
QB0
ROL
SUPJJ
SV3
TEORI
V9Y
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WVDHM
WXSBR
YCJ
AAFWJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
C1K
H94
K9.
7X8
ID FETCH-LOGICAL-c3537-4abcd819eacd8d5e9668849b4abeef6dba05f039e8a852554d743c296cb0516d3
ISSN 2326-5191
2326-5205
IngestDate Fri Jul 11 02:28:09 EDT 2025
Fri Jul 25 12:12:40 EDT 2025
Thu Apr 03 07:09:43 EDT 2025
Tue Jul 01 00:55:49 EDT 2025
Thu Apr 24 22:54:47 EDT 2025
Wed Jan 22 16:20:37 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2016, American College of Rheumatology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3537-4abcd819eacd8d5e9668849b4abeef6dba05f039e8a852554d743c296cb0516d3
Notes Dr. Sakkas has received speaking fees and/or honoraria from Bristol‐Myers Squibb, Novartis Hellas, Janssen‐Cilag, MSD, Pfizer Hellas, and Actelion (less than $10,000 each).
Dr. Katsiari has received speaking fees from Bristol‐Myers Squibb and Actelion (less than $10,000 each).
Presented in part at EULAR 2015, the 16th Annual European Congress of Rheumatology, Rome, Italy, June 2015.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 26414243
PQID 1759538640
PQPubID 946334
PageCount 11
ParticipantIDs proquest_miscellaneous_1760924084
proquest_journals_1759538640
pubmed_primary_26414243
crossref_primary_10_1002_art_39437
crossref_citationtrail_10_1002_art_39437
wiley_primary_10_1002_art_39437_ART39437
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 2016
2016-02-00
2016-Feb
20160201
PublicationDateYYYYMMDD 2016-02-01
PublicationDate_xml – month: 02
  year: 2016
  text: February 2016
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Atlanta
PublicationTitle Arthritis & rheumatology (Hoboken, N.J.)
PublicationTitleAlternate Arthritis Rheumatol
PublicationYear 2016
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2010; 12
2010; 32
2011; 235
2011; 117
2006; 54
2009; 60
2009; 182
1980; 23
2012; 180
2014; 1190
2008; 58
2011; 52
2002; 3
2008; 127
2012; 18
2008; 224
2013; 121
2009; 130
2006; 2
1988; 31
2014; 62
2013; 5
2012; 11
2006; 354
2006; 177
2014; 44
2003; 197
2014; 20
2012; 209
2012; 491
2012; 274
2010; 49
2013; 15
2004; 50
1997; 94
2010; 159
2013; 72
2005; 105
2008; 28
2000; 165
2002; 109
2013; 131
2012; 7
2003; 100
2003; 120
2011; 121
2014; 124
2014; 53
e_1_2_6_51_1
e_1_2_6_53_1
e_1_2_6_32_1
e_1_2_6_30_1
e_1_2_6_19_1
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_17_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_43_1
e_1_2_6_20_1
e_1_2_6_41_1
e_1_2_6_9_1
e_1_2_6_5_1
e_1_2_6_7_1
e_1_2_6_24_1
e_1_2_6_49_1
e_1_2_6_3_1
e_1_2_6_22_1
e_1_2_6_28_1
e_1_2_6_45_1
e_1_2_6_26_1
e_1_2_6_47_1
e_1_2_6_52_1
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_50_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_16_1
e_1_2_6_37_1
e_1_2_6_42_1
e_1_2_6_21_1
e_1_2_6_40_1
e_1_2_6_8_1
e_1_2_6_4_1
e_1_2_6_6_1
e_1_2_6_25_1
e_1_2_6_48_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_29_1
e_1_2_6_44_1
e_1_2_6_27_1
e_1_2_6_46_1
References_xml – volume: 117
  start-page: 530
  year: 2011
  end-page: 41
  article-title: Characterization of a rare IL‐10‐competent B‐cell subset in humans that parallels mouse regulatory B10 cells
  publication-title: Blood
– volume: 131
  start-page: 1204
  year: 2013
  end-page: 12
  article-title: IgG4 production is confined to human IL‐10‐producing regulatory B cells that suppress antigen‐specific immune responses
  publication-title: J Allergy Clin Immunol
– volume: 130
  start-page: 199
  year: 2009
  end-page: 212
  article-title: Role of the spleen in peripheral memory B‐cell homeostasis in patients with autoimmune thrombocytopenia purpura
  publication-title: Clin Immunol
– volume: 121
  start-page: 3274
  year: 2013
  end-page: 83
  article-title: Donor‐derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft‐versus‐host disease
  publication-title: Blood
– volume: 11
  start-page: 670
  year: 2012
  end-page: 7
  article-title: Human CD19 CD25 B regulatory cells suppress proliferation of CD4 T cells and enhance Foxp3 and CTLA‐4 expression in T‐regulatory cells
  publication-title: Autoimmun Rev
– volume: 53
  start-page: 1683
  year: 2014
  end-page: 92
  article-title: Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti‐neutrophil cytoplasmic antibody‐associated vasculitis in remission
  publication-title: Rheumatology (Oxford)
– volume: 58
  start-page: 3574
  year: 2008
  end-page: 84
  article-title: CD19 regulates the development of bleomycin‐induced pulmonary fibrosis in a mouse model
  publication-title: Arthritis Rheum
– volume: 32
  start-page: 129
  year: 2010
  end-page: 40
  article-title: CD19 CD24 CD38 B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients
  publication-title: Immunity
– volume: 105
  start-page: 4390
  year: 2005
  end-page: 8
  article-title: Identification and characterization of circulating human transitional B cells
  publication-title: Blood
– volume: 54
  start-page: 963
  year: 2006
  end-page: 73
  article-title: DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti‐topoisomerase I autoantibodies from systemic sclerosis patients
  publication-title: Arthritis Rheum
– volume: 12
  start-page: R54
  year: 2010
  article-title: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL‐6 modulation in an up to thirty‐six months follow‐up open‐label trial
  publication-title: Arthritis Res Ther
– volume: 177
  start-page: 1581
  year: 2006
  end-page: 9
  article-title: Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry
  publication-title: J Immunol
– volume: 120
  start-page: 542
  year: 2003
  end-page: 7
  article-title: Function blocking autoantibodies against matrix metalloproteinase‐1 in patients with systemic sclerosis
  publication-title: J Invest Dermatol
– volume: 15
  start-page: R168
  year: 2013
  article-title: B lymphocytes and B‐cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis
  publication-title: Arthritis Res Ther
– volume: 3
  start-page: 944
  year: 2002
  end-page: 50
  article-title: B cells regulate autoimmunity by provision of IL‐10
  publication-title: Nat Immunol
– volume: 94
  start-page: 208
  year: 1997
  end-page: 12
  article-title: Memory B lymphocytes migrate to bone marrow in humans
  publication-title: Proc Natl Acad Sci U S A
– volume: 60
  start-page: 578
  year: 2009
  end-page: 83
  article-title: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
  publication-title: Arthritis Rheum
– volume: 274
  start-page: 89
  year: 2012
  end-page: 97
  article-title: CD19 CD1d CD5 B cell frequencies are increased in patients with tuberculosis and suppress Th17 responses
  publication-title: Cell Immunol
– volume: 121
  start-page: 3645
  year: 2011
  end-page: 56
  article-title: Regulatory B cells are identified by expression of TIM‐1 and can be induced through TIM‐1 ligation to promote tolerance in mice
  publication-title: J Clin Invest
– volume: 23
  start-page: 581
  year: 1980
  end-page: 90
  article-title: Preliminary criteria for the classification of systemic sclerosis (scleroderma)
  publication-title: Arthritis Rheum
– volume: 209
  start-page: 1001
  year: 2012
  end-page: 10
  article-title: B cell depletion therapy ameliorates autoimmune disease through ablation of IL‐6‐producing B cells
  publication-title: J Exp Med
– volume: 127
  start-page: 14
  year: 2008
  end-page: 25
  article-title: Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation
  publication-title: Clin Immunol
– volume: 31
  start-page: 315
  year: 1988
  end-page: 24
  article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
  publication-title: Arthritis Rheum
– volume: 165
  start-page: 6635
  year: 2000
  end-page: 43
  article-title: Quantitative genetic variation in CD19 expression correlates with autoimmunity
  publication-title: J Immunol
– volume: 20
  start-page: 633
  year: 2014
  end-page: 41
  article-title: Interleukin‐35 induces regulatory B cells that suppress autoimmune disease
  publication-title: Nat Med
– volume: 124
  start-page: 2034
  year: 2014
  end-page: 45
  article-title: Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD
  publication-title: Blood
– volume: 62
  start-page: 266
  year: 2014
  end-page: 76
  article-title: IL‐10 production by B cells is differentially regulated by immune‐mediated and infectious stimuli and requires p38 activation
  publication-title: Mol Immunol
– volume: 100
  start-page: 12319
  year: 2003
  end-page: 24
  article-title: Systemic and cell type‐specific gene expression patterns in scleroderma skin
  publication-title: Proc Natl Acad Sci U S A
– volume: 224
  start-page: 201
  year: 2008
  end-page: 14
  article-title: Regulatory B cells as inhibitors of immune responses and inflammation
  publication-title: Immunol Rev
– volume: 491
  start-page: 264
  year: 2012
  end-page: 8
  article-title: Regulatory B cells control T‐cell autoimmunity through IL‐21‐dependent cognate interactions
  publication-title: Nature
– volume: 72
  start-page: 1416
  year: 2013
  end-page: 9
  article-title: Regulatory B cells in ANCA‐associated vasculitis
  publication-title: Ann Rheum Dis
– volume: 50
  start-page: 1897
  year: 2004
  end-page: 908
  article-title: Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome
  publication-title: Arthritis Rheum
– volume: 105
  start-page: 282
  year: 2005
  end-page: 8
  article-title: Stabilization of IFN‐γ mRNA by MAPK p38 in IL‐12‐ and IL‐18‐stimulated human NK cells
  publication-title: Blood
– volume: 52
  start-page: 851
  year: 2011
  end-page: 5
  article-title: IL‐10 is predominantly produced by CD19 CD5 regulatory B cell subpopulation: characterisation of CD19 and CD19 subpopulations of CD5 B cells
  publication-title: Yonsei Med J
– volume: 5
  start-page: 173ra23
  year: 2013
  article-title: CD19 CD24 CD38 B cells maintain regulatory T cells while limiting T 1 and T 17 differentiation
  publication-title: Sci Transl Med
– volume: 44
  start-page: 2121
  year: 2014
  end-page: 9
  article-title: TLR‐mediated STAT3 and ERK activation controls IL‐10 secretion by human B cells
  publication-title: Eur J Immunol
– volume: 159
  start-page: 176
  year: 2010
  end-page: 84
  article-title: Autoantibody‐mediated regulation of B cell responses by functional anti‐CD22 autoantibodies in patients with systemic sclerosis
  publication-title: Clin Exp Immunol
– volume: 49
  start-page: 271
  year: 2010
  end-page: 80
  article-title: Experience with rituximab in scleroderma: results from a 1‐year, proof‐of‐principle study
  publication-title: Rheumatology (Oxford)
– volume: 182
  start-page: 7459
  year: 2009
  end-page: 72
  article-title: The development and function of regulatory B cells expressing IL‐10 (B10 cells) requires antigen receptor diversity and TLR signals
  publication-title: J Immunol
– volume: 18
  start-page: 123
  year: 2012
  end-page: 37
  article-title: Multiple mechanisms of immune suppression by B lymphocytes
  publication-title: Mol Med
– volume: 7
  start-page: e49835
  year: 2012
  article-title: Decrease in proportion of CD19 CD24 CD27 B cells and impairment of their suppressive function in Graves’ disease
  publication-title: PLoS One
– volume: 50
  start-page: 1918
  year: 2004
  end-page: 27
  article-title: Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells
  publication-title: Arthritis Rheum
– volume: 354
  start-page: 2667
  year: 2006
  end-page: 76
  article-title: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis
  publication-title: N Engl J Med
– volume: 1190
  start-page: 45
  year: 2014
  end-page: 52
  article-title: Purification and immunophenotypic characterization of human B cells with regulatory functions
  publication-title: Methods Mol Biol
– volume: 197
  start-page: 489
  year: 2003
  end-page: 501
  article-title: Prevention of arthritis by interleukin 10‐producing B cells
  publication-title: J Exp Med
– volume: 53
  start-page: 1693
  year: 2014
  end-page: 703
  article-title: Regulatory B cells are numerically but not functionally deficient in anti‐neutrophil cytoplasm antibody‐associated vasculitis
  publication-title: Rheumatology (Oxford)
– volume: 15
  start-page: S1
  issue: Suppl 1
  year: 2013
  article-title: IL‐10‐producing regulatory B cells (B10 cells) in autoimmune disease
  publication-title: Arthritis Res Ther
– volume: 180
  start-page: 2375
  year: 2012
  end-page: 85
  article-title: IL‐10‐producing regulatory B10 cells ameliorate collagen‐induced arthritis via suppressing Th17 cell generation
  publication-title: Am J Pathol
– volume: 109
  start-page: 1453
  year: 2002
  end-page: 62
  article-title: CD19‐dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight‐skin mouse
  publication-title: J Clin Invest
– volume: 235
  start-page: 9
  year: 2011
  end-page: 17
  article-title: Recent insights into the mechanism of action of glatiramer acetate
  publication-title: J Neuroimmunol
– volume: 2
  start-page: 679
  year: 2006
  end-page: 85
  article-title: Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis
  publication-title: Nat Clin Pract Rheumatol
– volume: 28
  start-page: 639
  year: 2008
  end-page: 50
  article-title: A regulatory B cell subset with a unique CD1d CD5 phenotype controls T cell‐dependent inflammatory responses
  publication-title: Immunity
– ident: e_1_2_6_39_1
  doi: 10.1016/j.cellimm.2012.01.007
– ident: e_1_2_6_6_1
  doi: 10.4049/jimmunol.165.11.6635
– ident: e_1_2_6_23_1
  doi: 10.4049/jimmunol.0900270
– ident: e_1_2_6_7_1
  doi: 10.1172/JCI0215078
– ident: e_1_2_6_12_1
  doi: 10.1111/j.1365-2249.2009.04059.x
– ident: e_1_2_6_25_1
  doi: 10.1002/art.1780310302
– ident: e_1_2_6_19_1
  doi: 10.1182/blood-2004-11-4284
– ident: e_1_2_6_31_1
  doi: 10.1016/j.molimm.2014.05.018
– ident: e_1_2_6_52_1
  doi: 10.1073/pnas.94.1.208
– ident: e_1_2_6_24_1
  doi: 10.1002/art.1780230510
– ident: e_1_2_6_16_1
  doi: 10.1182/blood-2010-07-294249
– ident: e_1_2_6_13_1
  doi: 10.1186/ar4352
– ident: e_1_2_6_34_1
  doi: 10.1093/rheumatology/keu149
– ident: e_1_2_6_47_1
  doi: 10.2119/molmed.2011.00333
– ident: e_1_2_6_46_1
  doi: 10.1172/JCI46274
– ident: e_1_2_6_33_1
  doi: 10.1136/annrheumdis-2012-202986
– ident: e_1_2_6_49_1
  doi: 10.1002/art.20274
– ident: e_1_2_6_41_1
  doi: 10.1038/nm.3554
– ident: e_1_2_6_48_1
  doi: 10.1084/jem.20111675
– ident: e_1_2_6_51_1
  doi: 10.1002/art.20276
– ident: e_1_2_6_2_1
  doi: 10.1038/ncprheum0346
– ident: e_1_2_6_42_1
  doi: 10.1111/j.1600-065X.2008.00661.x
– ident: e_1_2_6_28_1
  doi: 10.1007/978-1-4939-1161-5_4
– ident: e_1_2_6_36_1
  doi: 10.1371/journal.pone.0049835
– ident: e_1_2_6_26_1
  doi: 10.1182/blood-2004-07-2782
– ident: e_1_2_6_8_1
  doi: 10.1002/art.23995
– ident: e_1_2_6_40_1
  doi: 10.1016/j.autrev.2011.11.018
– ident: e_1_2_6_14_1
  doi: 10.1038/ni833
– ident: e_1_2_6_38_1
  doi: 10.1016/j.immuni.2008.03.017
– ident: e_1_2_6_11_1
  doi: 10.1046/j.1523-1747.2003.12097.x
– ident: e_1_2_6_45_1
  doi: 10.1016/j.jneuroim.2011.01.009
– ident: e_1_2_6_44_1
  doi: 10.1182/blood-2012-11-465658
– ident: e_1_2_6_5_1
  doi: 10.1093/rheumatology/kep093
– ident: e_1_2_6_9_1
  doi: 10.1002/art.21646
– ident: e_1_2_6_53_1
  doi: 10.1186/ar2965
– ident: e_1_2_6_3_1
  doi: 10.1073/pnas.1635114100
– ident: e_1_2_6_30_1
  doi: 10.3349/ymj.2011.52.5.851
– ident: e_1_2_6_4_1
  doi: 10.1002/art.24249
– ident: e_1_2_6_22_1
  doi: 10.1126/scitranslmed.3005407
– ident: e_1_2_6_35_1
  doi: 10.1093/rheumatology/keu136
– ident: e_1_2_6_37_1
  doi: 10.1016/j.jaci.2013.01.014
– ident: e_1_2_6_10_1
  doi: 10.1056/NEJMoa052955
– ident: e_1_2_6_17_1
  doi: 10.1186/ar3907
– ident: e_1_2_6_21_1
  doi: 10.1016/j.immuni.2009.11.009
– ident: e_1_2_6_29_1
  doi: 10.1182/blood-2014-04-571125
– ident: e_1_2_6_20_1
  doi: 10.1016/j.clim.2007.11.013
– ident: e_1_2_6_32_1
  doi: 10.1002/eji.201344341
– ident: e_1_2_6_27_1
  doi: 10.4049/jimmunol.177.3.1581
– ident: e_1_2_6_43_1
  doi: 10.1016/j.ajpath.2012.03.010
– ident: e_1_2_6_15_1
  doi: 10.1084/jem.20021293
– ident: e_1_2_6_18_1
  doi: 10.1038/nature11501
– ident: e_1_2_6_50_1
  doi: 10.1016/j.clim.2008.09.009
SSID ssj0000970605
Score 2.5354347
Snippet Objective Breg cells, a regulatory cell subset that produces interleukin‐10 (IL‐10), play a significant role in suppressing autoimmune responses and preventing...
Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing...
Objective Breg cells, a regulatory cell subset that produces interleukin-10 (IL-10), play a significant role in suppressing autoimmune responses and preventing...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 494
SubjectTerms ADP-ribosyl Cyclase 1 - immunology
Adult
Aged
Antigens, CD19 - immunology
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - immunology
B-Lymphocytes, Regulatory - immunology
Case-Control Studies
CD24 Antigen - immunology
Female
Flow Cytometry
Humans
Interleukin-10 - immunology
Lymphocyte Activation
Lymphocyte Count
Male
Middle Aged
p38 Mitogen-Activated Protein Kinases - immunology
Pulmonary Fibrosis - etiology
Pulmonary Fibrosis - immunology
Receptors, Antigen, B-Cell
Scleroderma, Systemic - complications
Scleroderma, Systemic - immunology
Severity of Illness Index
STAT3 Transcription Factor - immunology
Toll-Like Receptor 9
Tumor Necrosis Factor Receptor Superfamily, Member 7 - immunology
Title Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.39437
https://www.ncbi.nlm.nih.gov/pubmed/26414243
https://www.proquest.com/docview/1759538640
https://www.proquest.com/docview/1760924084
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuiHcXCjKIA9JqlzzsbHIMFdW2UA6whd4iO5nQqFGCkg0S_C5-IGM7MVm1lQqXaGWPkqzns2fG8XxDyCtX-JHIcX5D6uZzFkg-DwEDV57mmWSBvwxzzfb5MVidsKNTfjqZ_B6dWuo2cpH-ujSv5H-0im2oV5Ul-w-atTfFBvyN-sUrahiv19Lx2wa-zfahLNtZ3ABG_ubzS1n-xHVEuYMtaCbW2QFaL7Pph12HuAIU6th5USmG_kLnuH1V-7GGvrxIccaXgOazaMe-a9xszjQFkoZLcwYderuGwgnd1FUt63Pos7eOFqMdhmPxQ5Vi6Epzoi9Wm_WiLWrrzX9GvOj-zhxZAgyVG2suvog-by1WCZdD64dCtOf1mB9hawPDtWeeh3UOfTrEhmuKdi1g1OY5fLxQB-EIkN5o1WWmTnJvwLmpZ3zBNhiuWVTWwo-YYZrZ5t-2QvxKMcMU_Gmtu26Qmx4GJzqQP3xvd_acSDEScV3VsP9nA6WV472xN952hC5EN9vBkvZ21nfJnT5MobHB3D0ygeo-uXXcH8R4QKSCHtXQQyGgI-hRCz2K0KNj6NEBerSo6AA9qqBHB-hRC72H5OTg3Xp_Ne_LdcxTn_vLORMyzdDBRFOehRkHDKTDkEUS2wHyIJPC4bnjRxCKkGMkyzL0XlMvClKJliHI_Edkp6or2CWUQcakE0lFL8jQzIgsD5mTwxJcmTInnJLXw9glac9lr0qqlIlh4fYSHOZED_OUvLSi3w2By2VCe4MCkn5-twk61hG6AwFzpuSF7cbVV31SExXUnZIJnEixBLIpeWwUZ5-CoYZKI_XxZbUmr358MiDqyfVFn5LbfyfTHtnZNB08Q_94I59rOP4BkkK53g
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Breg+Cells+Are+Numerically+Decreased+and+Functionally+Impaired+in+Patients+With+Systemic+Sclerosis&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Mavropoulos%2C+Athanasios&rft.au=Simopoulou%2C+Theodora&rft.au=Varna%2C+Areti&rft.au=Liaskos%2C+Christos&rft.date=2016-02-01&rft.issn=2326-5191&rft.eissn=2326-5205&rft.volume=68&rft.issue=2&rft.spage=494&rft.epage=504&rft_id=info:doi/10.1002%2Fart.39437&rft.externalDBID=10.1002%252Fart.39437&rft.externalDocID=ART39437
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon